Reata Pharmaceuticals Reacquires Rights to Bardoxolne
October 10 2019 - 7:49AM
Dow Jones News
By Chris Wack
Reata Pharmaceuticals Inc. (RETA), said Thursday it reacquired
development, manufacturing and commercialization rights concerning
its proprietary Nrf2 activator product platform originally licensed
to AbbVie Inc. (ABBV) for territories outside of the U.S. with
respect to bardoxolone methyl and worldwide with respect to
omaveloxolone and other next-generation Nrf2 activators.
The Texas-based biopharmaceutical company said it now possesses
exclusive, worldwide rights to develop, manufacture and
commercialize bardoxolone methyl, omaveloxolone, and all other
next-generation Nrf2 activators, excluding certain Asian markets
for bardoxolone, which are licensed to Kyowa Kirin Co. Ltd.
Reata said AbbVie will receive $330 million in cash, primarily
for rights to bardoxolone. Reata will make an upfront payment of
$75 million in 2019, with the remainder payable in installments in
the second quarter of 2020 and in the fourth quarter of 2021. In
addition, AbbVie will receive low single-digit, tiered royalties
from worldwide sales of omaveloxolone and certain next-generation
Nrf2 activators, and no royalties on bardoxolone.
Reata also said it has entered into an amendment to its loan and
security agreement with Oxford Finance LLC and Silicon Valley Bank.
The amended agreement makes $75 million available to Reata upon
positive, topline, registrational data from either the Cardinal
study of bardoxolone methyl in patients with Alport syndrome or the
MOXIe study of omaveloxolone in patients with Friedreich's ataxia.
The term loan facility increased by $30 million to $155
million.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 10, 2019 07:34 ET (11:34 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024